



theranos	LDT Validation Report	Theranos Creatine Kinase Assay CL RPT-14046	Rev: 1
	Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma	
Originator: Curtis Schneider		Date: 09/25/2013	

Validation of Modified Creatine Kinase (CK) Assay


Author(s):

Signature: 	Date: 11/7/13
Name: Paul Patel, Ph.D.	Title: Team Lead, General Chemistry

Reviewer(s):

Signature:	Date:
Name:	Title:
Signature:  SURAJ SAHANI	Date: 11/7/13
Name: Daniel Young, Ph.D.	Title: Vice President

Approver(s):

Signature: 	Date: 11/7/13
Name: Adam Rosendorff, M.D.	Title: Laboratory Director


Sunil S. Dhawan M.D.

9/19/15

Theranos Confidential

Page 1 of 14

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

TMP-00009 Rev. A, Released 08/01/13

theranos	LDT Validation Report	Theranos Creatine Kinase Assay	Rev:
		CL RPT-14046	1
Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	

Creatine Kinase Plasma Assay

- I. Overview**
- II. Method Principle**
- III. Definitions and Abbreviations**
- IV. Pre-clinical Validation**
 - a. Analytical Measurement Range
 - i. Limits of Blank, Detection and Quantitation
 - ii. Linearity
 - b. Analytical Specificity
 - c. Precision
- V. Clinical Validation**
 - a. Method Comparison with Predicate
 - b. Transference and Verification of Reference Interval (Venous)
 - c. Verification of Reference Interval with Finger Stick Samples
- VI. Stability**
 - a. Reagent
 - b. Sample
 - c. Calibrators

Theranos Internal Only

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

theranos	LDT Validation Report	Theranos Creatine Kinase Assay CL RPT-14046	Rev: 1
	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Description		Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma	
Originator: Curtis Schneider		Date: 09/25/2013	

I. Overview

Creatine Kinase (CK) activity is greatest in striated muscle, heart tissue and brain. The determination of CK activity is a proven tool in the investigation of skeletal muscle disease (mucular dystrophy) and is also useful in the diagnosis of myocardial infarction (MI) and cerebrovascular accidents. Increased levels of CK also can be found in viral myositis, polymyositis, and hypothyroidism.

Following injury to the myocardium, such as occurs in acute MI, CK is released from the damaged myocardial cells. A rise in the CK activity can be found 4 to 8 hours after an infarction.

II. Method Principle

Creatine Kinase reacts with the creatine phosphate and ADP to form ATP which is coupled to the hexokinase-G6PD reaction, generating NADPH. The concentration of NADPH is measured by the increase in absorbance at 340/410 nm.

Reaction Equation



III. Definitions and Abbreviations

The following definitions and abbreviations are used in this document and related documents and attachments:

theranos	LDT Validation Report	Theranos Creatine Kinase Assay	Rev:
		CL RPT-14046	1
Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	

- a. **Accuracy:** Accuracy is defined by CLSI as the closeness of agreement between a test result and an accepted reference value. Method accuracy is used in a different sense by the American Association of Pharmaceutical Scientists where it is expressed as percent relative error (%RE). Trueness, a related CLSI term, is the closeness of agreement between the average of a number of replicate measured quantity values and a reference quantity value.
- b. **Analyte:** Component represented in the name of a measurable quantity. The closely related term measurand is defined as the particular quantity subject to measurement.
- c. **Analytical sensitivity:** There are several alternative uses of this term. Most commonly, and for the purposes of this Validation Plan, it is used interchangeably with limit of detection. It is also used to describe the ability of an analytical method to assess small variations of the concentration of an analyte, such as the slope of the calibration curve (IUPAC).
- d. **Analytical specificity:** Ability of a test or procedure to correctly identify or quantify an entity, including in the presence of interfering substance(s) or phenomena.
- e. **Calibration:** Set of operations that establish, under specified conditions, the relationship between values of quantities indicated by a measuring instrument or measuring system, or values represented by a material measure or a reference material, and the corresponding values realized by standards. Under CLIA, calibration refers to the process of testing and adjusting an instrument, kit, or test system, to provide a known relationship between the measurement response and the value of the substance being measured by the test procedure (42 CFR 493.1217).
- f. **Calibrator:** A substance, material, or article intended to be used to establish the measurement relationships of a diagnostic medical device.
- g. **CLIA:** Clinical Laboratory Improvement Amendments of 1988. Congressional legislation that defined and requires specific quality assurance practices in clinical laboratories.
- h. **CLSI:** Clinical and Laboratory Standards Institute.
- i. **Coefficient of Variation:** The ratio of the standard deviation to the average, often multiplied by 100 and expressed as a percentage, abbreviated as %CV .

Theranos Confidential

Page 4 of 14

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

TMP-00009 Rev. A, Released 08/01/13

theranos	LDT Validation Report	Theranos Creatine Kinase Assay	Rev:
		CL RPT-14046	1
Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	

- j. **Colorimetry:** A technique used to determine the concentration of colored compound(s) in solution.
- k. **Interfering substance:** A substance or quantity thereof that is not the measurand but that affects the result of the measurement.
- l. **IUPAC:** International Union of Pure and Applied Chemistry
- m. **LDT:** Laboratory –developed Test.
- n. **Linearity:** Linearity is the ability of a quantitative analytical method to provide results that are directly proportional to the concentrations of an analyte in test samples, within a given measuring interval. It is an important parameter to confirm when evaluating an analytical method because it verifies correct interpolation of results between points.
- o. **LMR:** Lower end of the measuring range is the lowest level at which defined conditions, including all stated characteristic of the method, are met.
- p. **LoB:** Limit of Blank is the highest value in a series of results on a sample that contains no analyte.
- q. **LoD:** Limit of Detection is the lowest amount of analyte in a sample that can be detected with stated probability, although perhaps not quantified as an exact value.
- r. **LoQ:** When used without a prefix, the Limit of Quantitation is the lowest actual concentration at which an analyte is reliably detected and at which uncertainty of the test result is less than or equal to the goal set by the manufacturer or laboratory. The term may also be used with prefixes L for lower (LLOQ) and U for upper (ULOQ), respectively. Note: $LoB < LoD \leq LoQ$.
- s. **Matrix:** All components of a material system, except the analyte. A specimen matrix is the biological milieu in which an analyte exists (e.g., plasma, serum, urine, or other body fluids).

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

theranos	LDT Validation Report	Theranos Creatine Kinase Assay CL RPT-14046	Rev: 1
	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Description		Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma	
Originator: Curtis Schneider		Date: 09/25/2013	

- t. **Measuring Interval (reportable range; analytical measurement range or AMR):**
A measuring interval consists of all numeric values between the lower and upper numeric values for which a method can produce quantitative results suitable for clinical use. Where applicable, a linearity study is frequently used to establish or verify the measuring interval that can be reported for a measurement method. Alternatively, the lower limit of the measuring interval may be assigned as the ~~LoQ~~ (LLOQ).
- u. **Precision:** Precision is the closeness of agreement between indications or measured quantity values obtained by replicate measurements on the same or similar objects under specified conditions. It is usually expressed numerically in terms of standard deviation (SD) or percent Coefficient of Variation (%CV).
- v. **Reference interval:** The interval between and including two reference limits. It is common practice to define a reference limit so a stated fraction of the reference values is less than or equal, or greater than or equal, to the respective upper or lower limit.
- w. **SOP:** Standard Operating Procedure.
- x. **Spectrophotometry:** The quantitative measurement of the transmission (or reflection) properties of a material as a function of wavelength.
- y. **Testing System:** The entirety of the testing process, including instrument, sample, reagents, supplies, and procedures. Personnel are sometimes included in the definition.

Theranos Confidential

Page 6 of 14

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

TMP-00009 Rev. A, Released 08/01/13

theranos	LDT Validation Report	Theranos Creatine Kinase Assay	Rev:
		CL RPT-14046	1
Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	

IV. Pre-clinical Validation

a. Analytical Measurement Range

i. Limits of Blank, Detection and Quantitation

The limits of blank, detection, and quantitation were determined to be 0.6 mg/dL, 1.9 mg/dL, and 1.9 mg/dL, respectively.

Limit of blank

CLSI guideline EP17-A section 4.3.1

Level	Number of samples	N	Mean	SD
Blank	1	20	0.1	0.3
Alpha	5%			
Parametric LoB	0.6			

Limit of detection

CLSI guideline EP17-A section 4.3.2

Level	Number of samples	N	Pooled SD
Low	1	20	0.8
Beta	5%		
Parametric LoD	1.9		

Limit of quantitation

CLSI guideline EP17-A section 5.1

Level	Number of samples	N
Low	1	20
Bias	1.0	
Pooled Imprecision	0.8	
95% total error	2.4	
Allowable error	20	
LoQ	1.9	

95% total error is less than allowable error: 20 U/L.

LoQ has been established.

Theranos Confidential

Page 7 of 14

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

TMP-00009 Rev. A, Released 08/01/13

theranos	LDT Validation Report	Theranos Creatine Kinase Assay	Rev:
		CL RPT-14046	1
Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	

ii. Linearity

The Analytical Measurement Range (AMR) including linear measurement interval has been determined by Siemens. Refer to the Analytical Range section of the manufacturer product information insert for additional details

b. Analytical Specificity

The analytical specificity for this assay has been determined by Siemens. Refer to the Interference section of the manufacturer product information insert for additional details.

c. Precision

Level = L1

Number of observations	80
Number of runs	40
Number of days	20
Runs per day	2
Replicates per run	2

Mean 78.8

	SD	95% CI	CV
Repeatability	1.3	1.1 to 1.7	1.7%
Between-run	0.0		0.0%
Between-day	1.4		1.8%
Within-laboratory	2.0	1.6 to 2.5	2.5%

theranos	LDT Validation Report	Theranos Creatine Kinase Assay	Rev:
		CL RPT-14046	1
Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	

Level = L2

Number of observations	78
Number of runs	39
Number of runs excluded	1
Number of days	20
% of days with 1 run	5%
Runs per day	2
Replicates per run	2

10/1

CLSI guideline EP05-A2 section 10.4 recommends a minimum of 40 runs

Mean	240.9		
	SD	95% CI	CV
Repeatability	5.7	4.7 to 7.3	2.4%
Between-run	0.0		0.0%
Between-day	13.5		5.6%
Within-laboratory	14.7	11.5 to 20.4	6.1%

~ ~ ~ / / /

Level = L3

Number of observations	80
Number of runs	40
Number of days	20
Runs per day	2
Replicates per run	2

Mean	622.3		
	SD	95% CI	CV
Repeatability	14.3	11.8 to 18.4	2.3%
Between-run	0.0		0.0%
Between-day	29.0		4.7%
Within-laboratory	32.3	25.4 to 44.5	5.2%

The percent CV reported as zeros in the above precision summary are most likely a consequence of rounding the values in StatisPro.

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

theranos	LDT Validation Report	Theranos Creatine Kinase Assay	Rev:
		CL RPT-14046	1
Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	

V. Clinical Validation

a. Method Comparison with Predicate (Accuracy/Comparability)

To test the accuracy of the assay on the Theranos System, fifty (50) unique patient samples were screened on the predicate method (Siemens, Advia) and on the Theranos method. Using the predicate method forty (40) values were within the reference range (Males: 32- 294 U/L; Females 33 – 211 U/L), one (1) was below the reference range, and nine (9) were above the reference range. Based on the results of the data examination, either a simple linear regression or alternative procedures were used to estimate expected (average) bias and the confidence interval of expected bias at the desired medical decision level(s) as per CLSI guidance EP09-A2. StatisPro was used for bias calculations. These estimates were compared with internal criteria to judge the acceptability of the Theranos method. Each sample was run in duplicate on the predicate, and the average used for comparison to the Theranos method. Some samples were stored before analysis on both methods. If the confidence interval for the predicted bias includes the defined acceptable bias or if the acceptable bias is greater than the higher limit of the confidence interval of the predicted bias, then the data do not show that the bias of the Theranos method is different from the acceptable bias or there is a high probability (97%) that the predicted bias is acceptable, respectively. The acceptable bias at each medical decision level was determined based on the total allowable error (TEa) minus the measured precision at the level closest to that decision level. Total allowable error (TEa) was taken from American Proficiency Institute (API) peer proficiency testing criteria or CLIA proficiency testing criteria for acceptable analytical performance, as printed in the Federal Register February 28, 1992;57(40):7002-186, when available. The TEa for Creatine Kinase is 30%. The table below shows the allowable bias and precision at 2 levels (values shown in parentheses) and the corresponding closest medical decision limits.

Table 1. Allowable Bias and Precision at the Medical Decision Levels

Medical Decision Levels (U/L)	100 (78.8)	240 (240.9)	1800 (622.3)
Precision (%)	1.8	5.6	4.7
Allowable Bias (%)	28.2	24.4	25.3

Theranos Confidential

Page 10 of 14

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

TMP-00009 Rev. A, Released 08/01/13

theranos	LDT Validation Report	Theranos Creatine Kinase Assay	Rev:
		CL RPT-14046	1
Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	




Figure 1. Graph showing Theranos method versus Predicate Method (Siemens Advia). Simple linear regression was used to establish a slope, intercept and an r^2 . The slope, intercept and clinical correlation were determined to be 1.08, -13.39 and 1.00 respectively.

Comparability

CLSI guideline EP09-A2-PR section 7

Level ID	Value	Difference	SE	95% CI	Allowable difference
	100	-6.7	9.66	-26.3 to 12.9	24.0
	240	4.5	9.30	-14.3 to 23.4	67.6
	1800	129.8	12.62	104.2 to 155.5	432.0

Difference is less than allowable bias: 24%.

The difference between the two methods is not greater than the allowable difference. The performance requirement is verified.

b. Transference and Verification of Reference Interval (Venous)

Reference ranges were modified by applying the regression equation to the lower and upper reference limits of existing reference interval to generate a new reference range. New reference ranges were verified using a total of seventy two (male 30 and female 42) new normal subjects with matched venous and finger sticks samples. For a reference range to pass verification, 95% of values should fall within the upper and lower reference limits and 5% or fewer values fall outside of the upper and lower reference limits. For venous verification with the male population group 30 (100%) values fell within the new reference range and 0 (0%) values fell outside the new reference range. For the female population group 42 (100%) values fell within the new reference range and 0 (0%) values fell outside the new reference range See graphs below for male and female venous samples verification.

theranos	LDT Validation Report	Theranos Creatine Kinase Assay CL RPT-14046	Rev: 1
	Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma	
Originator: Curtis Schneider		Date: 09/25/2013	




Figure 2. Graph showing male & female venous sample reference range verification.

c. Verification of Reference Interval with Finger Stick Samples

New reference ranges were also verified with venous matched finger sticks from a total of seventy six (31 males & 45 females) new normal subjects. For finger stick verification 31 values (100%) for the male group and 43 values (95.6%) for female group fell within the new reference range and 2 (4.4%) values for the female group fell outside the new reference range. See graphs below for finger stick samples verification.

theranos	LDT Validation Report	Theranos Creatine Kinase Assay	Rev:
		CL RPT-14046	1
Description	Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	




Figure 3. Graphs showing males & females finger stick sample reference range verification.

Theranos Analyte	Anti-coagulant	Existing Reference Range (mg/dL)		New Reference Range (mg/dL)	
		Reference Range (low)	Reference Range (High)	Transferred RR (low)	Transferred RR (high)
Creatine Kinase (Male)	Heparin	32.0	294.0	21.0	304.0
Creatine Kinase (Female)	Heparin	33.0	211.0	22.0	214.0

The new reference range for finger stick Creatine Kinase for male and female groups were determined to be 21 – 304 U/L & 22 – 214 U/L respectively.

VI. Stability

a. Reagents

On-board Reagent Stability

Theranos Confidential

Page 13 of 14

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

TMP-00009 Rev. A, Released 08/01/13

theranos	LDT Validation Report	Theranos Creatine Kinase Assay CL RPT-14046	Rev: 1
	Description: Validation Report for Modified Siemens Assay for Creatine Kinase (CK) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 09/25/2013	

System	Stability
ADVIA 1200	10 days
ADVIA 1650/1800	10 days
ADVIA 2400	10 days

Unopened Creatinine reagents are stable at 2-8 °C until the expiration date printed on the product label. Do not freeze reagents.

b. Sample

Plasma samples for Creatinine analysis are stable for 2 weeks at 2-8 °C, or at least 90 days at -20 °C.

c. Calibrators

Siemens Chemistry Calibrators should be stored at 2-8 °C, protected from light, and are stable until the expiration date on the vial label. Opened calibrators are stable for 48 hours, except for total and direct, which are stable for 8 hours.

REVISION HISTORY			
Revision Level	Effective Date	Initiator	ECO Number
A	11/06/2013	A. Rosendorff	CL ECO-00117
Section Number	Description and Justification of Changes		
All	Initial Release		

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.